Effect of naringenin on the pharmacokinetics of metoprolol succinate in rats

References

• Ademola AO, Temidayo OO, Olumuyiwa AA. 2020. Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/angiotensin converting enzyme (ACE)/kidney injury molecule (Kim-1) signaling pathway. Eur J Pharmacol. 880:173142.
   Google Scholar
• Alnaqeeb M, Mansor KA, Mallah EM, Ghanim BY, Idkaidek N, Qinna NA. 2019. Critical pharmacokinetic and pharmacodynamic drug-herb interactions in rats between warfarin and pomegranate peel or guava leaves extracts. BMC Complement Altern Med. 19(1):29.
   PubMed Web of Science ®Google Scholar
• Badary OA, Maksoud SA, Ahmed WA, Owieda GH. 2005. Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci. 76(18):2125–2135.
   PubMed Web of Science ®Google Scholar
• Benfield P, Clissold SP, Brogden RN. 1986. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs. 31(5):376–429.
   PubMed Web of Science ®Google Scholar
• Benjamin B, Fabio B, Urs D, Stephan K, Manuel H. 2018. Cytochrome P450 enzymes involved in metoprolol metabolism and use of metoprolol as a CYP2D6 phenotyping probe drug. Front Pharmacol. 24:774.
   Google Scholar
• Burkina V, Zlabek V, Halsne R, Ropstad E, Zamaratskaia G. 2016. In vitro effects of the Citrus flavonoids diosmin, naringenin and naringin on the hepatic drug-metabolizing CYP3A enzyme in human, pig, mouse and fish. Biochem Pharmacol. 110-111:109–116.
   PubMed Web of Science ®Google Scholar
• Candida JR, Robbie AB, Juan JLL, Frank LG, Eric R, David MR, Alexander P, Brandon JK, Hector FC, Shawn RC, et al. 2020. Safety and pharmacokinetics of naringenin: a randomized, controlled, single-ascending-dose clinical trial. Diabetes Obes Metab. 22:91–98.
   PubMed Web of Science ®Google Scholar
• Challa VR, Babu PR, Challa SR, Johnson B, Maheswari C. 2013. Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Drug Dev Ind Pharm. 39(6):865–872.
   PubMed Web of Science ®Google Scholar
• Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. 2002. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 360(9343):1347–1360.
   PubMed Web of Science ®Google Scholar
• Gao K, Henning SM, Niu Y, Youssefian AA, Seeram NP, Xu A, Heber D. 2006. The citrus flavonoid naringenin stimulates DNA repair in prostate cancer cells. J Nutr Biochem. 17(2):89–95.
   PubMed Web of Science ®Google Scholar
• Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. 2008. Epidemiology and causation of coronary heart disease and stroke in India. Heart. 94(1):16–26.
   PubMed Web of Science ®Google Scholar
• Jeon S-M, Kim HK, Kim H-J, Do G-M, Jeong T-S, Park YB, Choi M-S. 2007. Hypocholesterolemic and antioxidative effects of naringenin and its two metabolites in high-cholesterol fed rats. Transl Res. 149(1):15–21.
   PubMed Web of Science ®Google Scholar
• Kallem RR, Ramesh M, Seshagirirao JVLN. 2013. Validated LC-ESI-MS/MS method for simultaneous quantitation of felodipine and metoprolol in rat plasma: application to a pharmacokinetic study in rats. Biomed Chromatogr. 27(6):784–791.
   PubMed Web of Science ®Google Scholar
• Keech AC, Harper RW, Harrison PM, Pitt A, McLean AJ. 1986. Verapamil appears to increase the bioavailability of metoprolol. Amencan Journal of Cardiology. 58(6):551–552.
   PubMed Web of Science ®Google Scholar
• Kendall MJ, Maxwell SR, Sandberg A, Westergren G. 1991. Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 21(5):319–330.
   PubMed Web of Science ®Google Scholar
• Lee C-H, Jeong T-S, Choi Y-K, Hyun B-H, Oh G-T, Kim E-H, Kim J-R, Han J-I, Bok S-H. 2001. Antiatherogenic effect of citrus flavonoid, naringin and naringenin associated with hepatic ACAT and acrostic VCAM-1 and MCP-1 in high cholesterol fed rabbits. Biochem Biophys Res Commun. 284(3):681–688.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu H, Zeng Q. 2019. The effect of naringenin on the pharmacokinetics of ibrutinib in rat: a drug–drug interaction study. Biomed Chromatogr. 33(5):e4507.
   PubMed Web of Science ®Google Scholar
• Ravindra BP, Sridhar V, Surya SM, Siddhartha N, Sivaprasad P, Naveen BK. 2016. Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in Wistar rats. Drug Dev Ind Pharm. 42:1110–1117.
   PubMed Web of Science ®Google Scholar
• Raza SS, Khan MM, Ahmad A, Ashafaq M, Islam F, Wagner AP, Safhi MM, Islam F. 2013. Neuroprotective effect of naringenin is mediated through suppression of NF-κB signaling pathway in experimental stroke . Neuroscience. 230:157–171.
   PubMed Web of Science ®Google Scholar
• Renugadevi J, Milton Prabu S. 2010. Cadmium-induced hepatotoxicity in rats and the protective effect of naringenin. Exp Toxicol Pathol. 62(2):171–181.
   PubMed Web of Science ®Google Scholar
• Rice EC, Miller NG, Paganga G. 1996. Structure antioxidant activity relationships of flavonoids and phenolic acids. Free Rad Biol Med. 20:833–956.
   Web of Science ®Google Scholar
• Surya SM, Sridhar V, Puneeth Y, Ravindra BP, Naveen BK. 2014. Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. Drug Dev Ind Pharm. 40(10):1371–1377.
   PubMed Web of Science ®Google Scholar
• Ting S, Yeh HS, Lien TF. 2011. Effects of supplemental levels of hesperetin and naringenin on egg quality, serum traits and antioxidant activity of laying hens. Anim Feed Sci Tech. 163:59–66.
   Web of Science ®Google Scholar
• Wang B, Shen J, Zhou Q, Meng D, He Y, Chen F, Wang S, Ji W. 2020. Effects of naringenin on the pharmacokinetics of tofacitinib in rats. Pharm Biol. 58(1):225–230.
   PubMed Web of Science ®Google Scholar
• Wenjie JL, Valentina F, Cong X, David AF, Salvatore C. 2011. Enantiomers of Naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms. Chirality. 23:891–896.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Lei X, Zhang T, Liu G, Yang M, Liu M. 2016. Influence of verapamil on pharmacokinetics of triptolide in rats. Eur J Drug Metab Pharmacokinet. 41(4):449–456.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wei J, Zhang H. 2019. Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. Xenobiotica. 49(5):563–568.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Song X, Dong G. 2019. Effects of verapamil on the pharmacokinetics of puerarin in rats. Xenobiotica. 49(10):1178–1182.
   PubMed Web of Science ®Google Scholar